p-Isobutylphenylacetamid | 40784-94-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: p-Isobutylphenylacetamid
• 英文别名: 2-[4-(2-Methylpropyl)phenyl]acetamide
• CAS: 40784-94-9
• 化学式: C₁₂H₁₇NO
• mdl: MFCD19348192
• 分子量: 191.273
• InChiKey: HHWNGEUSTSKRIK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  p-Isobutylphenylacetamid 在 劳森试剂 、 吡啶 作用下， 以 甲苯 为溶剂， 反应 8.0h， 生成 2-[(4-isobutylphenyl)methyl]-5-phenyl-4-hydroxythiazole
  参考文献：
  名称：

  Conversion of cyclooxygenase inhibitors into hydroxythiazole 5-lipoxygenase inhibitors

  摘要：

  Representative examples of NSAID cyclooxygenase inhibitors such as naproxen, ibufenac, ibuprofen, and butibufen have been transformed into 5-lipoxygenase inhibitors by replacement of the carboxylic acid moiety with a 4-hydroxythiazole group. (C) 1997, Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(96)00255-6
• 作为产物：
  描述：

  异丁芬酸 在 ammonium hydroxide 、 草酰氯 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 9.0h， 生成 p-Isobutylphenylacetamid
  参考文献：
  名称：

  Conversion of cyclooxygenase inhibitors into hydroxythiazole 5-lipoxygenase inhibitors

  摘要：

  Representative examples of NSAID cyclooxygenase inhibitors such as naproxen, ibufenac, ibuprofen, and butibufen have been transformed into 5-lipoxygenase inhibitors by replacement of the carboxylic acid moiety with a 4-hydroxythiazole group. (C) 1997, Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(96)00255-6

文献信息

• [EN] AZETIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES<br/>[FR] DÉRIVÉS D'AZÉTIDINE UTILES POUR LE TRAITEMENT DE MALADIES MÉTABOLIQUES ET INFLAMMATOIRES
  申请人：GALAPAGOS NV

  公开号：WO2012098033A1

  公开（公告）日：2012-07-26

  Compounds are disclosed that have a formula represented by the following: These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example inflammatory conditions, infectious diseases, autoimmune diseases, diseases involving impairment of immune cell functions, cardiometabolic diseases, and/or proliferative diseases.

  披露了具有以下表示的公式的化合物：这些化合物可以制备为药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，例如炎症性疾病、传染病、自身免疫疾病、涉及免疫细胞功能受损的疾病、心脏代谢疾病和/或增殖性疾病，举例不限。
• NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES
  申请人：Sanière Laurent Raymond Maurice

  公开号：US20130303515A1

  公开（公告）日：2013-11-14

  Compounds are disclosed that have a formula represented by the following: These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example inflammatory conditions, infectious diseases, autoimmune diseases, diseases involving impairment of immune cell functions, cardiometabolic diseases, and/or proliferative diseases.

  公开了具有以下式子表示的化合物：这些化合物可以制备成药物组合物，并可用于哺乳动物，包括人类的预防和治疗，例如炎症性疾病、传染病、自身免疫疾病、涉及免疫细胞功能受损的疾病、心脏代谢疾病和/或增殖性疾病等。
• Heterocyclic derivatives as modulators of ion channels
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：EP2308872A1

  公开（公告）日：2011-04-13

  The present invention relates to heterocyclic derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

  本发明涉及可用作离子通道抑制剂的杂环衍生物。本发明还提供了包含本发明化合物的药学上可接受的组合物，以及使用该组合物治疗各种疾病的方法。
• AZETIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES
  申请人：Galapagos NV

  公开号：EP2665704A1

  公开（公告）日：2013-11-27
• US5068251A
  申请人：——

  公开号：US5068251A

  公开（公告）日：1991-11-26